BioMarin Pharmaceutical Inc. (BMRN)
USD 62.03
(-1.08%)
USD 62.03
(-1.08%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 310.28 Million USD | 64.24% |
| 2022 | 267.51 Million USD | 232.14% |
| 2021 | 48.02 Million USD | 920.96% |
| 2020 | -5.85 Million USD | 73.7% |
| 2019 | 33.94 Million USD | 77.81% |
| 2018 | -3.54 Million USD | -39.82% |
| 2017 | 94.75 Million USD | 62.74% |
| 2016 | -705.52 Million USD | 33.02% |
| 2015 | -110.7 Million USD | -108.54% |
| 2014 | -49.95 Million USD | -15.97% |
| 2013 | -137.35 Million USD | -29.23% |
| 2012 | -79.83 Million USD | -187.67% |
| 2011 | -172 Thousand USD | -495.91% |
| 2010 | 17.06 Million USD | -63.03% |
| 2009 | 35.63 Million USD | -59.71% |
| 2008 | 67.44 Million USD | 202.4% |
| 2007 | -57.28 Million USD | -316.18% |
| 2006 | -14.88 Million USD | 76.51% |
| 2005 | -54.46 Million USD | -54.99% |
| 2004 | -134.63 Million USD | 26.72% |
| 2003 | -66.36 Million USD | -24.3% |
| 2002 | -59.12 Million USD | -77.13% |
| 2001 | -40.63 Million USD | -18.1% |
| 2000 | -29.94 Million USD | 4.85% |
| 1999 | -20.38 Million USD | -51.72% |
| 1998 | -12.1 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q3 | 113.89 Billion USD | -3.55% |
| 2024 Q1 | 109.21 Million USD | 160.96% |
| 2024 Q2 | 129.92 Million USD | 18.86% |
| 2023 Q4 | 41.08 Million USD | -15.33% |
| 2023 FY | - USD | 64.24% |
| 2023 Q2 | 82.19 Million USD | -5.41% |
| 2023 Q3 | 48.51 Million USD | -40.97% |
| 2023 Q1 | 86.88 Million USD | 718.07% |
| 2022 Q1 | 57.33 Million USD | 256.05% |
| 2022 Q3 | 27.57 Million USD | -56.9% |
| 2022 Q4 | 10.62 Million USD | -61.49% |
| 2022 FY | - USD | 232.14% |
| 2022 Q2 | 63.98 Million USD | 11.59% |
| 2021 Q2 | 45.2 Million USD | -17.83% |
| 2021 Q4 | -36.74 Million USD | -137.8% |
| 2021 Q1 | 55.01 Million USD | 427.55% |
| 2021 FY | - USD | 920.96% |
| 2021 Q3 | -15.45 Million USD | -134.18% |
| 2020 Q2 | -19.31 Million USD | -129.97% |
| 2020 FY | - USD | 73.7% |
| 2020 Q1 | 64.44 Million USD | 1455.61% |
| 2020 Q4 | -16.79 Million USD | 50.87% |
| 2020 Q3 | -34.19 Million USD | -77.03% |
| 2019 Q2 | -29.74 Million USD | -12.39% |
| 2019 Q1 | -26.46 Million USD | 54.98% |
| 2019 Q4 | 4.14 Million USD | -86.11% |
| 2019 FY | - USD | 77.81% |
| 2019 Q3 | 29.82 Million USD | 200.27% |
| 2018 Q4 | -58.78 Million USD | -620.3% |
| 2018 Q2 | -26.72 Million USD | -2.63% |
| 2018 FY | - USD | -39.82% |
| 2018 Q3 | 11.29 Million USD | 142.28% |
| 2018 Q1 | -26.04 Million USD | 32.12% |
| 2017 Q3 | -5.97 Million USD | 65.46% |
| 2017 FY | - USD | 62.74% |
| 2017 Q1 | 4.33 Million USD | 105.78% |
| 2017 Q4 | -38.36 Million USD | -541.84% |
| 2017 Q2 | -17.3 Million USD | -498.87% |
| 2016 FY | - USD | 33.02% |
| 2016 Q4 | -75.06 Million USD | -59.12% |
| 2016 Q3 | -47.17 Million USD | -280.64% |
| 2016 Q2 | 26.11 Million USD | 137.94% |
| 2016 Q1 | -68.84 Million USD | -0.5% |
| 2015 Q2 | -57.07 Million USD | 10.56% |
| 2015 Q4 | -68.5 Million USD | 14.05% |
| 2015 Q3 | -79.69 Million USD | -39.64% |
| 2015 FY | - USD | -108.54% |
| 2015 Q1 | -63.81 Million USD | -16.9% |
| 2014 Q4 | -54.58 Million USD | -4.51% |
| 2014 FY | - USD | -15.97% |
| 2014 Q1 | -16.56 Million USD | 60.94% |
| 2014 Q3 | -52.22 Million USD | -251.96% |
| 2014 Q2 | -14.83 Million USD | 10.4% |
| 2013 Q2 | -19.68 Million USD | 47.13% |
| 2013 Q1 | -37.24 Million USD | -5.6% |
| 2013 Q4 | -42.39 Million USD | -0.59% |
| 2013 FY | - USD | -29.23% |
| 2013 Q3 | -42.15 Million USD | -114.09% |
| 2012 Q3 | -8.6 Million USD | 69.56% |
| 2012 Q4 | -35.26 Million USD | -309.78% |
| 2012 FY | - USD | -187.67% |
| 2012 Q1 | -19.76 Million USD | -67.35% |
| 2012 Q2 | -28.26 Million USD | -43.01% |
| 2011 Q2 | 899 Thousand USD | -68.41% |
| 2011 Q3 | -12.36 Million USD | -1475.19% |
| 2011 Q4 | -11.81 Million USD | 4.46% |
| 2011 FY | - USD | -495.91% |
| 2011 Q1 | 2.84 Million USD | -39.49% |
| 2010 Q3 | 2.36 Million USD | -50.73% |
| 2010 Q2 | 4.79 Million USD | 21.58% |
| 2010 Q1 | 3.94 Million USD | -65.58% |
| 2010 FY | - USD | -63.03% |
| 2010 Q4 | 4.7 Million USD | 99.11% |
| 2009 FY | - USD | -59.71% |
| 2009 Q1 | 2.3 Million USD | -95.59% |
| 2009 Q4 | 11.45 Million USD | 9.0% |
| 2009 Q3 | 10.51 Million USD | 0.28% |
| 2009 Q2 | 10.48 Million USD | 354.16% |
| 2008 Q3 | 5.71 Million USD | -24.13% |
| 2008 Q2 | 7.53 Million USD | 294.4% |
| 2008 Q4 | 52.34 Million USD | 815.42% |
| 2008 Q1 | 1.91 Million USD | 123.09% |
| 2008 FY | - USD | 202.4% |
| 2007 Q2 | -12.5 Million USD | 20.44% |
| 2007 FY | - USD | -316.18% |
| 2007 Q1 | -15.72 Million USD | -74.65% |
| 2007 Q4 | -8.27 Million USD | 49.56% |
| 2007 Q3 | -16.4 Million USD | -31.18% |
| 2006 Q1 | -5.12 Million USD | 49.03% |
| 2006 FY | - USD | 76.51% |
| 2006 Q4 | -9 Million USD | -493.96% |
| 2006 Q3 | 2.28 Million USD | -6.31% |
| 2006 Q2 | 2.43 Million USD | 147.61% |
| 2005 Q4 | -10.05 Million USD | 6.46% |
| 2005 Q2 | -16.36 Million USD | 25.47% |
| 2005 Q1 | -21.96 Million USD | -23.24% |
| 2005 Q3 | -10.74 Million USD | 34.36% |
| 2005 FY | - USD | -54.99% |
| 2004 FY | - USD | 26.72% |
| 2004 Q3 | -20.41 Million USD | -195.99% |
| 2004 Q4 | -17.82 Million USD | 12.7% |
| 2004 Q2 | 21.26 Million USD | 224.48% |
| 2004 Q1 | -17.08 Million USD | 24.83% |
| 2003 Q1 | -18.45 Million USD | 30.68% |
| 2003 FY | - USD | -24.3% |
| 2003 Q4 | -22.72 Million USD | -28.13% |
| 2003 Q3 | -17.73 Million USD | -138.51% |
| 2003 Q2 | -7.43 Million USD | 51.08% |
| 2002 Q3 | -12.66 Million USD | -23.74% |
| 2002 Q4 | -24.36 Million USD | -112.59% |
| 2002 FY | - USD | -77.13% |
| 2002 Q1 | -11.29 Million USD | 171.36% |
| 2002 Q2 | -10.79 Million USD | -473.81% |
| 2001 FY | - USD | -18.1% |
| 2001 Q4 | -10.06 Million USD | 44.26% |
| 2001 Q3 | -7.47 Million USD | 18.4% |
| 2001 Q2 | -7.96 Million USD | -13.55% |
| 2001 Q1 | -6.54 Million USD | 13.1% |
| 2000 Q3 | -6.34 Million USD | -19.97% |
| 2000 Q4 | -8.02 Million USD | -21.08% |
| 2000 Q2 | -5.49 Million USD | -478.86% |
| 2000 Q1 | -5.8 Million USD | 86.35% |
| 2000 FY | - USD | 4.85% |
| 1999 FY | - USD | -51.72% |
| 1999 Q2 | -4.88 Million USD | 76.44% |
| 1999 Q3 | -5.8 Million USD | -17.78% |
| 1999 Q1 | -3.59 Million USD | 0.0% |
| 1999 Q4 | -6.74 Million USD | -14.49% |
| 1998 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Sangamo Therapeutics, Inc. | -87.42 Million USD | 454.906% |
| IDEAYA Biosciences, Inc. | -130.42 Million USD | 337.91% |
| Eton Pharmaceuticals, Inc. | -291 Thousand USD | 106726.804% |
| Autolus Therapeutics plc | -156.77 Million USD | 297.923% |
| Greenwich LifeSciences, Inc. | -9.32 Million USD | 3427.709% |
| Enlivex Therapeutics Ltd. | -28.21 Million USD | 1199.557% |
| Shattuck Labs, Inc. | -87.61 Million USD | 454.145% |
| LENZ Therapeutics, Inc. | -122.24 Million USD | 353.824% |
| CervoMed Inc. | -2.17 Million USD | 14386.464% |
| Rocket Pharmaceuticals, Inc. | -236.62 Million USD | 231.131% |
| Corbus Pharmaceuticals Holdings, Inc. | -44.43 Million USD | 798.261% |
| Aptose Biosciences Inc. | -52.26 Million USD | 693.64% |
| Precision BioSciences, Inc. | -32.04 Million USD | 1068.367% |
| Dyadic International, Inc. | -8.22 Million USD | 3870.278% |
| TScan Therapeutics, Inc. | -80.09 Million USD | 487.38% |
| Intensity Therapeutics, Inc. | -10.08 Million USD | 3176.383% |
| Nektar Therapeutics | -243.1 Million USD | 227.633% |
| CytomX Therapeutics, Inc. | -4.3 Million USD | 7300.835% |
| VYNE Therapeutics Inc. | -29.25 Million USD | 1160.51% |
| EyePoint Pharmaceuticals, Inc. | -69 Million USD | 549.68% |
| Leap Therapeutics, Inc. | -80.98 Million USD | 483.128% |
| Adaptive Biotechnologies Corporation | -189.27 Million USD | 263.935% |
| GRI Bio, Inc. | -10.89 Million USD | 2947.165% |
| Xenetic Biosciences, Inc. | -4.51 Million USD | 6971.204% |
| Tenaya Therapeutics, Inc. | -122.5 Million USD | 353.281% |
| NeuroSense Therapeutics Ltd. | -10.63 Million USD | 3018.123% |
| Psyence Biomedical Ltd. | -2.75 Million USD | 11376.576% |
| IGM Biosciences, Inc. | -253.35 Million USD | 222.469% |
| INmune Bio, Inc. | - USD | -Infinity% |
| Opthea Limited | -200.01 Million USD | 255.127% |
| Milestone Pharmaceuticals Inc. | -56.84 Million USD | 645.842% |
| Omega Therapeutics, Inc. | -93.49 Million USD | 431.89% |
| Verastem, Inc. | -83.16 Million USD | 473.09% |
| Abeona Therapeutics Inc. | -50.57 Million USD | 713.549% |
| Pliant Therapeutics, Inc. | -158.22 Million USD | 296.099% |
| Tonix Pharmaceuticals Holding Corp. | -114.08 Million USD | 371.967% |
| Ligand Pharmaceuticals Incorporated | 101.72 Million USD | -205.016% |
| NextCure, Inc. | -59.03 Million USD | 625.558% |
| Inhibikase Therapeutics, Inc. | -19.91 Million USD | 1658.246% |
| Organovo Holdings, Inc. | -14.8 Million USD | 2195.664% |
| Lixte Biotechnology Holdings, Inc. | 3207.00 USD | -9675110.477% |
| Arvinas, Inc. | -394.8 Million USD | 178.593% |
| Ovid Therapeutics Inc. | -58.71 Million USD | 628.474% |
| CASI Pharmaceuticals, Inc. | -21.53 Million USD | 1540.568% |
| Rani Therapeutics Holdings, Inc. | -65.27 Million USD | 575.334% |
| Centessa Pharmaceuticals plc | -166.06 Million USD | 286.844% |
| Arcturus Therapeutics Holdings Inc. | -24.16 Million USD | 1383.969% |
| Syros Pharmaceuticals, Inc. | -157.19 Million USD | 297.388% |
| Senti Biosciences, Inc. | -61.33 Million USD | 605.876% |
| BioRestorative Therapies, Inc. | -15.05 Million USD | 2160.998% |
| Apollomics, Inc. | -171.74 Million USD | 280.663% |
| PureTech Health plc | -11.62 Million USD | 2768.651% |
| Oncternal Therapeutics, Inc. | 2.23 Million USD | -13782.953% |
| Barinthus Biotherapeutics plc | -74.81 Million USD | 514.736% |
| Kymera Therapeutics, Inc. | -143.2 Million USD | 316.677% |
| Synaptogenix, Inc. | -8.3 Million USD | 3834.983% |
| ChromaDex Corporation | -3.89 Million USD | 8068.259% |
| Beam Therapeutics Inc. | -156.47 Million USD | 298.299% |
| Monopar Therapeutics Inc. | 429.03 Thousand USD | -72220.698% |
| Akebia Therapeutics, Inc. | -6.86 Million USD | 4617.822% |
| Nurix Therapeutics, Inc. | -141.4 Million USD | 319.423% |
| Apellis Pharmaceuticals, Inc. | -495.21 Million USD | 162.657% |
| Dermata Therapeutics, Inc. | 247.21 Thousand USD | -125411.294% |
| Gritstone bio, Inc. | -126.86 Million USD | 344.582% |
| Mesoblast Limited | -61.33 Million USD | 605.917% |
| Virpax Pharmaceuticals, Inc. | -2.24 Million USD | 13892.122% |
| Xeris Biopharma Holdings, Inc. | -23.73 Million USD | 1407.285% |
| Fate Therapeutics, Inc. | -172.22 Million USD | 280.158% |
| MediWound Ltd. | -4.89 Million USD | 6441.386% |
| BioXcel Therapeutics, Inc. | -165.42 Million USD | 287.572% |
| Fortress Biotech, Inc. | -133.64 Million USD | 332.174% |
| Fractyl Health, Inc. Common Stock | -50.55 Million USD | 713.816% |
| Achilles Therapeutics plc | -70.44 Million USD | 540.482% |
| Seres Therapeutics, Inc. | -85.43 Million USD | 463.186% |
| Checkpoint Therapeutics, Inc. | -52.14 Million USD | 695.007% |
| Atossa Therapeutics, Inc. | -31.35 Million USD | 1089.615% |
| Zai Lab Limited | -366.57 Million USD | 184.645% |
| Fresh Tracks Therapeutics, Inc. | -5.64 Million USD | 5593.697% |
| Lyell Immunopharma, Inc. | -225.24 Million USD | 237.752% |
| Vanda Pharmaceuticals Inc. | -10.94 Million USD | 2935.716% |
| Tarsus Pharmaceuticals, Inc. | -131.67 Million USD | 335.653% |
| InMed Pharmaceuticals Inc. | -7.06 Million USD | 4492.512% |
| FibroGen, Inc. | -261.4 Million USD | 218.699% |
| Celcuity Inc. | -58.3 Million USD | 632.129% |
| SeaStar Medical Holding Corporation | -11.14 Million USD | 2885.064% |
| ContextLogic Inc. | -324 Million USD | 195.767% |
| GH Research PLC | -41.15 Million USD | 853.977% |
| HOOKIPA Pharma Inc. | -77.34 Million USD | 501.179% |
| Cyclacel Pharmaceuticals, Inc. | -25.42 Million USD | 1320.533% |
| ImmuCell Corporation | -2.5 Million USD | 12491.153% |
| Amylyx Pharmaceuticals, Inc. | 39.89 Million USD | -677.849% |
| Amarin Corporation plc | -50.9 Million USD | 709.577% |
| TG Therapeutics, Inc. | 26.1 Million USD | -1088.828% |
| Aptevo Therapeutics Inc. | -28.31 Million USD | 1195.984% |
| Jasper Therapeutics, Inc. | -64.98 Million USD | 577.47% |
| Foghorn Therapeutics Inc. | -104.45 Million USD | 397.05% |
| Y-mAbs Therapeutics, Inc. | -25.67 Million USD | 1308.648% |
| Aptorum Group Limited | -9.59 Million USD | 3332.463% |
| Ultragenyx Pharmaceutical Inc. | -516.45 Million USD | 160.08% |
| BioCryst Pharmaceuticals, Inc. | -116.33 Million USD | 366.716% |
| Chemomab Therapeutics Ltd. | -25.39 Million USD | 1321.975% |
| Arrowhead Pharmaceuticals, Inc. | -175.67 Million USD | 276.627% |
| TransCode Therapeutics, Inc. | -17.97 Million USD | 1826.346% |
| RAPT Therapeutics, Inc. | -125.84 Million USD | 346.558% |
| Ardelyx, Inc. | -55.35 Million USD | 660.545% |
| Ainos, Inc. | -8.77 Million USD | 3636.767% |
| Lyra Therapeutics, Inc. | -65.25 Million USD | 575.531% |
| Prothena Corporation plc | -190.1 Million USD | 263.215% |
| HilleVax, Inc. | -132.46 Million USD | 334.237% |
| Adaptimmune Therapeutics plc | -128.19 Million USD | 342.035% |
| Celularity Inc. | -183.94 Million USD | 268.682% |
| Rallybio Corporation | -72.37 Million USD | 528.729% |
| Cue Biopharma, Inc. | -46.05 Million USD | 773.769% |
| Omeros Corporation | -163.61 Million USD | 289.649% |
| Humacyte, Inc. | -96.45 Million USD | 421.678% |
| Immunocore Holdings plc | -59.64 Million USD | 620.183% |
| Cocrystal Pharma, Inc. | -19.37 Million USD | 1701.714% |
| Blueprint Medicines Corporation | -474.61 Million USD | 165.376% |
| IO Biotech, Inc. | -91.22 Million USD | 440.119% |
| MEI Pharma, Inc. | 26.38 Million USD | -1076.209% |
| GT Biopharma, Inc. | 5.97 Million USD | -5089.563% |
| Cabaletta Bio, Inc. | -73.23 Million USD | 523.688% |
| Summit Therapeutics Inc. | 1 Million USD | -30897.403% |
| Alaunos Therapeutics, Inc. | -30.9 Million USD | 1104.025% |
| Marinus Pharmaceuticals, Inc. | -125.49 Million USD | 347.244% |
| Scholar Rock Holding Corporation | -168.45 Million USD | 284.198% |
| Pulmatrix, Inc. | -12.64 Million USD | 2553.614% |
| Elicio Therapeutics, Inc. | -32.96 Million USD | 1041.224% |
| X4 Pharmaceuticals, Inc. | -107.1 Million USD | 389.706% |
| Vigil Neuroscience, Inc. | -88.46 Million USD | 450.734% |
| Acelyrin, Inc. | -381.52 Million USD | 181.327% |
| Intellia Therapeutics, Inc. | -506.31 Million USD | 161.283% |
| Cytokinetics, Incorporated | -456.68 Million USD | 167.943% |
| Vor Biopharma Inc. | -114.37 Million USD | 371.296% |
| Evogene Ltd. | -23.2 Million USD | 1437.2% |
| Replimune Group, Inc. | -230.19 Million USD | 234.79% |
| Applied Therapeutics, Inc. | -64.53 Million USD | 580.8% |
| PDS Biotechnology Corporation | -40.08 Million USD | 874.066% |
| Hoth Therapeutics, Inc. | -153.14 Thousand USD | 202702.694% |
| BridgeBio Pharma, Inc. | -565.46 Million USD | 154.872% |
| AEON Biopharma, Inc. | -48.36 Million USD | 741.6% |
| BioLineRx Ltd. | -57.06 Million USD | 643.776% |
| Galectin Therapeutics Inc. | -202 Thousand USD | 153705.941% |
| Atai Life Sciences N.V. | -36.31 Million USD | 954.518% |
| Aerovate Therapeutics, Inc. | -81.31 Million USD | 481.592% |
| VistaGen Therapeutics, Inc. | -32.45 Million USD | 1056.103% |
| Zentalis Pharmaceuticals, Inc. | -275.5 Million USD | 212.625% |
| Sagimet Biosciences Inc. | -30.74 Million USD | 1109.382% |
| MediciNova, Inc. | -9.87 Million USD | 3240.536% |
| Praxis Precision Medicines, Inc. | -125.94 Million USD | 346.373% |
| MiMedx Group, Inc. | 40.51 Million USD | -665.812% |
| Cardio Diagnostics Holdings, Inc. | -1.53 Million USD | 20377.336% |
| Axsome Therapeutics, Inc. | -224.99 Million USD | 237.91% |
| PTC Therapeutics, Inc. | -330.34 Million USD | 193.929% |
| Mereo BioPharma Group plc | -26.05 Million USD | 1290.835% |
| Syndax Pharmaceuticals, Inc. | -229.94 Million USD | 234.94% |
| NRx Pharmaceuticals, Inc. | -30.02 Million USD | 1133.419% |
| Dyne Therapeutics, Inc. | -233.47 Million USD | 232.898% |
| BriaCell Therapeutics Corp. | -4.79 Million USD | 6575.763% |
| Allakos Inc. | -189.91 Million USD | 263.38% |
| scPharmaceuticals Inc. | -46.06 Million USD | 773.637% |
| Fulcrum Therapeutics, Inc. | -108.49 Million USD | 385.997% |
| Corcept Therapeutics Incorporated | 108.32 Million USD | -186.441% |
| NLS Pharmaceutics AG | -11.79 Million USD | 2730.494% |
| Precigen, Inc. | -89.22 Million USD | 447.751% |
| XOMA Corporation | -39.36 Million USD | 888.283% |
| Kezar Life Sciences, Inc. | -99.25 Million USD | 412.616% |
| Incyte Corporation | 919.42 Million USD | 66.252% |
| Alzamend Neuro, Inc. | -9.88 Million USD | 3238.333% |
| Cara Therapeutics, Inc. | -117.65 Million USD | 363.735% |
| Aligos Therapeutics, Inc. | -83.81 Million USD | 470.201% |
| Seer, Inc. | -97.88 Million USD | 416.988% |
| Reviva Pharmaceuticals Holdings, Inc. | -24.11 Million USD | 1386.85% |
| CRISPR Therapeutics AG | -202.7 Million USD | 253.075% |
| Akero Therapeutics, Inc. | -148.63 Million USD | 308.761% |
| Eliem Therapeutics, Inc. | -13.65 Million USD | 2372.643% |
| EyeGate Pharmaceuticals, Inc. | -8.04 Million USD | 3958.15% |
| Akari Therapeutics, Plc | -16.8 Million USD | 1946.709% |
| Novavax, Inc. | -487.39 Million USD | 163.662% |
| Lexaria Bioscience Corp. | -6.38 Million USD | 4956.82% |
| UroGen Pharma Ltd. | -63.83 Million USD | 586.102% |
| Sutro Biopharma, Inc. | -67.91 Million USD | 556.871% |
| Entera Bio Ltd. | -8.8 Million USD | 3624.353% |
| Lisata Therapeutics, Inc. | -25.51 Million USD | 1315.894% |
| Stoke Therapeutics, Inc. | -112.3 Million USD | 376.289% |
| Chimerix, Inc. | -92.97 Million USD | 433.732% |
| Reneo Pharmaceuticals, Inc. | -82.23 Million USD | 477.323% |
| Phathom Pharmaceuticals, Inc. | -159.04 Million USD | 295.087% |
| Outlook Therapeutics, Inc. | -57.37 Million USD | 640.791% |
| Jazz Pharmaceuticals plc | 1.44 Billion USD | 78.593% |
| AnaptysBio, Inc. | -143.16 Million USD | 316.733% |
| Aprea Therapeutics, Inc. | -14.27 Million USD | 2272.902% |
| Portage Biotech Inc. | -18.19 Million USD | 1804.951% |
| Olema Pharmaceuticals, Inc. | -104.58 Million USD | 396.684% |
| PMV Pharmaceuticals, Inc. | -78.87 Million USD | 493.387% |
| OKYO Pharma Limited | -15.74 Thousand USD | 1970673.871% |
| Qualigen Therapeutics, Inc. | -11.3 Million USD | 2845.788% |
| Cadrenal Therapeutics, Inc. Common Stock | -8.33 Million USD | 3821.322% |
| Processa Pharmaceuticals, Inc. | -11.45 Million USD | 2808.286% |
| AbCellera Biologics Inc. | -192.15 Million USD | 261.473% |
| Genprex, Inc. | -31.06 Million USD | 1098.964% |
| Neumora Therapeutics, Inc. Common Stock | -187.52 Million USD | 265.462% |
| NLS Pharmaceutics AG | -11.79 Million USD | 2730.494% |
| Virios Therapeutics, Inc. | 150.9 Thousand USD | -205516.816% |
| Daré Bioscience, Inc. | -30.7 Million USD | 1110.647% |
| Titan Pharmaceuticals, Inc. | -7.16 Million USD | 4430.551% |
| Bicycle Therapeutics plc | -183.4 Million USD | 269.184% |
| Revolution Medicines, Inc. Warrant | -430.58 Million USD | 172.062% |
| Protagonist Therapeutics, Inc. | -90.34 Million USD | 443.462% |
| Erasca, Inc. | -121.31 Million USD | 355.778% |
| bluebird bio, Inc. | -167.16 Million USD | 285.62% |
| Pieris Pharmaceuticals, Inc. | -22.76 Million USD | 1463.167% |
| DBV Technologies S.A. | -85.98 Million USD | 460.871% |
| Fortress Biotech, Inc. | -133.64 Million USD | 332.174% |
| Avidity Biosciences, Inc. | -233.49 Million USD | 232.886% |
| CorMedix Inc. | -48.88 Million USD | 734.696% |
| Travere Therapeutics, Inc. | -326.24 Million USD | 195.107% |
| Sensei Biotherapeutics, Inc. | -33.38 Million USD | 1029.384% |
| Orchestra BioMed Holdings, Inc. | -51.21 Million USD | 705.799% |
| Spruce Biosciences, Inc. | -47.36 Million USD | 755.077% |
| Celldex Therapeutics, Inc. | -139.03 Million USD | 323.171% |
| Cartesian Therapeutics, Inc. | -235.06 Million USD | 232.0% |
| Cogent Biosciences, Inc. | -205.86 Million USD | 250.726% |
| Onconetix, Inc. | -36.7 Million USD | 945.306% |
| Ocuphire Pharma, Inc. | -9.96 Million USD | 3212.801% |
| Prime Medicine, Inc. | -193.75 Million USD | 260.139% |
| Adagene Inc. | -14.95 Million USD | 2175.369% |
| Inhibrx Biosciences, Inc. | -206.69 Million USD | 250.118% |
| GlycoMimetics, Inc. | -39.12 Million USD | 893.119% |
| Maravai LifeSciences Holdings, Inc. | 712.4 Million USD | 56.446% |
| Verve Therapeutics, Inc. | -217.66 Million USD | 242.549% |
| Voyager Therapeutics, Inc. | 126.45 Million USD | -145.371% |
| SciSparc Ltd. | -5.28 Million USD | 5974.366% |
| Revelation Biosciences, Inc. | -95.2 Thousand USD | 326001.185% |
| Minerva Neurosciences, Inc. | -21.69 Million USD | 1530.445% |
| Astria Therapeutics, Inc. | -83.03 Million USD | 473.701% |
| Spero Therapeutics, Inc. | 27.15 Million USD | -1042.682% |
| Tevogen Bio Holdings Inc. | 188.7 Thousand USD | -164327.204% |
| Arcutis Biotherapeutics, Inc. | -227.43 Million USD | 236.428% |
| Marker Therapeutics, Inc. | -11.79 Million USD | 2731.249% |
| Alnylam Pharmaceuticals, Inc. | -258.24 Million USD | 220.152% |
| Artelo Biosciences, Inc. | -10.28 Million USD | 3116.86% |
| 2seventy bio, Inc. | -206.41 Million USD | 250.318% |
| ADMA Biologics, Inc. | 5.12 Million USD | -5960.234% |
| Clene Inc. | -43.24 Million USD | 817.569% |
| Capricor Therapeutics, Inc. | -23 Million USD | 1448.535% |
| Boundless Bio, Inc. Common Stock | -48.47 Million USD | 740.064% |
| Recursion Pharmaceuticals, Inc. | -299.56 Million USD | 203.578% |
| Citius Pharmaceuticals, Inc. | -36.72 Million USD | 944.785% |
| Contineum Therapeutics, Inc. Class A Common Stock | 23.57 Million USD | -1216.269% |
| Absci Corporation | -95.45 Million USD | 425.051% |
| Regeneron Pharmaceuticals, Inc. | 4.65 Billion USD | 93.333% |
| Surrozen, Inc. | -41.13 Million USD | 854.38% |
| Caribou Biosciences, Inc. | -112.53 Million USD | 375.725% |
| Janux Therapeutics, Inc. | -71.02 Million USD | 536.872% |
| Cingulate Inc. | -22.95 Million USD | 1451.88% |
| Galmed Pharmaceuticals Ltd. | -7.46 Million USD | 4258.745% |
| Tenax Therapeutics, Inc. | -8.22 Million USD | 3871.821% |
| Jaguar Health, Inc. | -33.13 Million USD | 1036.537% |
| Terns Pharmaceuticals, Inc. | -102.26 Million USD | 403.409% |
| ACADIA Pharmaceuticals Inc. | -67.82 Million USD | 557.464% |
| Kronos Bio, Inc. | -121.83 Million USD | 354.686% |
| Innoviva, Inc. | 248.96 Million USD | -24.632% |
| Bolt Biotherapeutics, Inc. | -74.34 Million USD | 517.374% |
| Entrada Therapeutics, Inc. | -321 Thousand USD | 96761.682% |
| ZyVersa Therapeutics, Inc. | -107.74 Million USD | 387.984% |
| Soligenix, Inc. | -7.85 Million USD | 4051.228% |
| AlloVir, Inc. | -190.14 Million USD | 263.182% |
| Century Therapeutics, Inc. | -121.2 Million USD | 355.993% |
| ORIC Pharmaceuticals, Inc. | -109.74 Million USD | 382.724% |
| Kura Oncology, Inc. | -164.95 Million USD | 288.102% |
| Ocean Biomedical, Inc. | -957.73 Thousand USD | 32497.553% |
| Mineralys Therapeutics, Inc. | -84.65 Million USD | 466.519% |
| Eterna Therapeutics Inc. | -19.93 Million USD | 1656.557% |
| SELLAS Life Sciences Group, Inc. | 529 Thousand USD | -58554.82% |
| Heron Therapeutics, Inc. | -103.79 Million USD | 398.948% |
| SAB Biotherapeutics, Inc. | -38.13 Million USD | 913.684% |
| Pasithea Therapeutics Corp. | -15.33 Million USD | 2123.912% |
| Entero Therapeutics, Inc. | -15.74 Million USD | 2070.903% |
| HCW Biologics Inc. | -23.57 Million USD | 1416.098% |
| C4 Therapeutics, Inc. | -122.1 Million USD | 354.117% |
| Atara Biotherapeutics, Inc. | -265.99 Million USD | 216.649% |
| Coherus BioSciences, Inc. | -193.93 Million USD | 259.991% |
| Lantern Pharma Inc. | -15.78 Million USD | 2065.479% |
| Histogen Inc. | -10.5 Million USD | 3054.242% |
| Surrozen, Inc. | -41.13 Million USD | 854.38% |
| Eledon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Kodiak Sciences Inc. | -259.02 Million USD | 219.79% |
| MoonLake Immunotherapeutics | -54.1 Million USD | 673.433% |
| Hepion Pharmaceuticals, Inc. | -49.25 Million USD | 729.91% |
| Adverum Biotechnologies, Inc. | -112.59 Million USD | 375.566% |
| Avalo Therapeutics, Inc. | -27.95 Million USD | 1209.941% |
| Moderna, Inc. | -3.28 Billion USD | 109.451% |
| Ionis Pharmaceuticals, Inc. | -230.01 Million USD | 234.9% |
| Turnstone Biologics Corp. | -56.23 Million USD | 651.773% |
| Immix Biopharma, Inc. | -16.13 Million USD | 2022.972% |
| Tiziana Life Sciences Ltd | -15.33 Million USD | 2122.844% |
| Aurinia Pharmaceuticals Inc. | -63.04 Million USD | 592.147% |
| Exelixis, Inc. | 196.6 Million USD | -57.823% |
| Monte Rosa Therapeutics, Inc. | -137.08 Million USD | 326.338% |
| Wave Life Sciences Ltd. | -58.79 Million USD | 627.784% |
| Conduit Pharmaceuticals Inc. | -324 Thousand USD | 95866.667% |
| Alkermes plc | 495.04 Million USD | 37.323% |
| Jasper Therapeutics, Inc. | -64.98 Million USD | 577.47% |
| Arcellx, Inc. | -64.14 Million USD | 583.723% |
| ESSA Pharma Inc. | -26.45 Million USD | 1272.861% |
| TNF Pharmaceuticals, Inc. | -3.99 Million USD | 7857.205% |
| Avid Bioservices, Inc. | -11.48 Million USD | 2802.587% |
| Insmed Incorporated | -654.73 Million USD | 147.39% |
| Cardiff Oncology, Inc. | -45.01 Million USD | 789.306% |
| Enanta Pharmaceuticals, Inc. | -123.47 Million USD | 351.291% |
| Moolec Science SA | -52.07 Million USD | 695.834% |
| RenovoRx, Inc. | -11.39 Million USD | 2824.179% |
| Acumen Pharmaceuticals, Inc. | -51.6 Million USD | 701.256% |
| Geron Corporation | -174.78 Million USD | 277.526% |
| LAVA Therapeutics N.V. | -40.41 Million USD | 867.707% |
| Verrica Pharmaceuticals Inc. | -62.19 Million USD | 598.873% |
| Royalty Pharma plc | 1.88 Billion USD | 83.559% |
| OmniAb, Inc. | -49.73 Million USD | 723.925% |
| Alector, Inc. | -142.89 Million USD | 317.146% |
| Atea Pharmaceuticals, Inc. | -119.59 Million USD | 359.45% |
| Mersana Therapeutics, Inc. | -166.08 Million USD | 286.828% |
| Humacyte, Inc. | -96.45 Million USD | 421.678% |
| Structure Therapeutics Inc. | -102.45 Million USD | 402.837% |
| Revance Therapeutics, Inc. | -290.63 Million USD | 206.76% |
| 89bio, Inc. | -134.46 Million USD | 330.758% |
| Avenue Therapeutics, Inc. | 4.05 Million USD | -7557.552% |
| Aura Biosciences, Inc. | -83.69 Million USD | 470.727% |
| Immunic, Inc. | -99.11 Million USD | 413.064% |
| Veracyte, Inc. | -49.4 Million USD | 727.991% |
| Genelux Corporation | -24.16 Million USD | 1384.022% |
| Trevi Therapeutics, Inc. | -33.8 Million USD | 1018.0% |
| Adial Pharmaceuticals, Inc. | -7 Million USD | 4531.788% |
| Sonnet BioTherapeutics Holdings, Inc. | -18.71 Million USD | 1757.777% |
| Immunovant, Inc. | -269.97 Million USD | 214.929% |
| Vericel Corporation | 2.86 Million USD | -10733.939% |
| Fortrea Holdings Inc. | 167.3 Million USD | -85.466% |
| KalVista Pharmaceuticals, Inc. | -134.28 Million USD | 331.072% |
| XBiotech Inc. | -35.76 Million USD | 967.539% |
| Agenus Inc. | -145.92 Million USD | 312.634% |
| Acasti Pharma Inc. | -11.3 Million USD | 2845.633% |
| Kiora Pharmaceuticals, Inc. | -12.35 Million USD | 2612.416% |
| MiNK Therapeutics, Inc. | -22.25 Million USD | 1494.332% |
| Pasithea Therapeutics Corp. | -15.33 Million USD | 2123.912% |
| Theravance Biopharma, Inc. | -40.86 Million USD | 859.253% |
| Metagenomi, Inc. Common Stock | -56.02 Million USD | 653.871% |
| NeuroBo Pharmaceuticals, Inc. | -15.88 Million USD | 2053.929% |
| Gain Therapeutics, Inc. | -22.16 Million USD | 1499.595% |
| Tempest Therapeutics, Inc. | -28.77 Million USD | 1178.274% |
| Sol-Gel Technologies Ltd. | -28.96 Million USD | 1171.312% |
| Rhythm Pharmaceuticals, Inc. | -168.46 Million USD | 284.184% |
| United Therapeutics Corporation | 1.38 Billion USD | 77.626% |
| Creative Medical Technology Holdings, Inc. | -5.52 Million USD | 5715.443% |
| BriaCell Therapeutics Corp. | -4.77 Million USD | 6602.539% |
| Lixte Biotechnology Holdings, Inc. | 3207.00 USD | -9675110.477% |
| Silo Pharma, Inc. | -3.62 Million USD | 8656.693% |
| Telomir Pharmaceuticals, Inc. Common Stock | -6.11 Million USD | 5172.863% |
| Pharming Group N.V. | 9.87 Million USD | -3041.48% |
| XOMA Corporation | -39.36 Million USD | 888.283% |
| Reviva Pharmaceuticals Holdings, Inc. | -24.11 Million USD | 1386.85% |
| Bionomics Limited | -9.83 Million USD | 3254.256% |
| Alpha Tau Medical Ltd. | -34.6 Million USD | 996.619% |
| Pyxis Oncology, Inc. | -78.49 Million USD | 495.301% |
| uniQure N.V. | -253.1 Million USD | 222.593% |
| Xilio Therapeutics, Inc. | -73.8 Million USD | 520.416% |
| Cassava Sciences, Inc. | -95.68 Million USD | 424.27% |
| 60 Degrees Pharmaceuticals, Inc. | -1.42 Million USD | 21850.733% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | 1639.183% |
| Poseida Therapeutics, Inc. | -129.5 Million USD | 339.594% |
| Pluri Inc. | -20.22 Million USD | 1634.161% |
| Anebulo Pharmaceuticals, Inc. | -8.05 Million USD | 3954.233% |
| MeiraGTx Holdings plc | -57.05 Million USD | 643.862% |
| Cidara Therapeutics, Inc. | -24.36 Million USD | 1373.482% |
| ProMIS Neurosciences, Inc. | -17.8 Million USD | 1842.221% |
| CalciMedica, Inc. | -34.18 Million USD | 1007.555% |
| Sana Biotechnology, Inc. | -252.39 Million USD | 222.938% |
| Amicus Therapeutics, Inc. | -92.07 Million USD | 436.976% |
| Salarius Pharmaceuticals, Inc. | -12.88 Thousand USD | 2408223.003% |
| Alpha Tau Medical Ltd. | -34.6 Million USD | 996.619% |
| Adlai Nortye Ltd. American Depositary Shares | -101.21 Million USD | 406.559% |
| Nutriband Inc. | -5.12 Million USD | 6158.132% |
| Protara Therapeutics, Inc. | -43.27 Million USD | 817.055% |
| Compugen Ltd. | -12.51 Million USD | 2579.099% |
| Roivant Sciences Ltd. | -996.51 Million USD | 131.137% |
| ProKidney Corp. | -147.66 Million USD | 310.121% |
| Protagenic Therapeutics, Inc. | -4.49 Million USD | 6997.107% |
| Elevai Labs, Inc. Common Stock | -4.27 Million USD | 7366.021% |
| Tango Therapeutics, Inc. | -111.75 Million USD | 377.639% |
| Renovaro Biosciences Inc. | -79.51 Million USD | 490.211% |
| Zevra Therapeutics, Inc. | -48.59 Million USD | 738.471% |
| Benitec Biopharma Inc. | -22.49 Million USD | 1479.653% |
| GeoVax Labs, Inc. | -26.66 Million USD | 1263.473% |
| Biomea Fusion, Inc. | -124.62 Million USD | 348.984% |
| Cullinan Oncology, Inc. | -190.33 Million USD | 263.017% |
| 4D Molecular Therapeutics, Inc. | -107.11 Million USD | 389.666% |
| Kiniksa Pharmaceuticals, Ltd. | -22.85 Million USD | 1457.62% |
| Nuvectis Pharma, Inc. | -22.89 Million USD | 1455.129% |
| Spyre Therapeutics, Inc. | -242.3 Million USD | 228.056% |
| Ventyx Biosciences, Inc. | -207.83 Million USD | 249.293% |
| Imunon, Inc. | -19.87 Million USD | 1660.92% |
| BioAtla, Inc. | -122.24 Million USD | 353.83% |
| Allogene Therapeutics, Inc. | -300.29 Million USD | 203.327% |
| Larimar Therapeutics, Inc. | -41.44 Million USD | 848.628% |
| Zura Bio Limited | -60.56 Million USD | 612.333% |
| aTyr Pharma, Inc. | -52.17 Million USD | 694.664% |
| Madrigal Pharmaceuticals, Inc. | -379.96 Million USD | 181.66% |
| Viridian Therapeutics, Inc. | -234.56 Million USD | 232.281% |
| Galecto, Inc. | -37.51 Million USD | 927.005% |
| Tevogen Bio Holdings Inc. | 188.7 Thousand USD | -164327.204% |
| Halozyme Therapeutics, Inc. | 451.94 Million USD | 31.345% |
| Lexicon Pharmaceuticals, Inc. | -163.46 Million USD | 289.818% |
| PolyPid Ltd. | -20.26 Million USD | 1631.284% |
| Aileron Therapeutics, Inc. | -15.61 Million USD | 2087.344% |
| Forte Biosciences, Inc. | -32.47 Million USD | 1055.396% |
| Xencor, Inc. | -125.87 Million USD | 346.504% |
| Coeptis Therapeutics Holdings, Inc. | -20.15 Million USD | 1639.289% |
| Lexaria Bioscience Corp. | -6.38 Million USD | 4956.82% |
| Instil Bio, Inc. | -146.12 Million USD | 312.346% |
| Cardio Diagnostics Holdings, Inc. | -1.53 Million USD | 20377.336% |
| OncoCyte Corporation | -23.12 Million USD | 1441.885% |
| Elevation Oncology, Inc. | -41.46 Million USD | 848.267% |
| Purple Biotech Ltd. | -22.22 Million USD | 1496.103% |
| CollPlant Biotechnologies Ltd. | -6.41 Million USD | 4940.624% |
| MacroGenics, Inc. | 2.01 Million USD | -15283.441% |
| Verona Pharma plc | -52.46 Million USD | 691.382% |
| Tharimmune, Inc. | -9.3 Million USD | 3435.459% |
| Apogee Therapeutics, Inc. | -83.98 Million USD | 469.452% |
| enGene Holdings Inc. Warrants | -94.77 Million USD | 427.4% |
| Aditxt, Inc. | -25.45 Million USD | 1318.809% |
| XTL Biopharmaceuticals Ltd. | -764 Thousand USD | 40713.089% |
| Savara Inc. | -59.13 Million USD | 624.722% |
| Curis, Inc. | -45.13 Million USD | 787.397% |
| Carmell Therapeutics Corporation | -15.19 Million USD | 2142.532% |
| Achieve Life Sciences, Inc. | -26.73 Million USD | 1260.634% |
| BeiGene, Ltd. | -1.12 Billion USD | 127.59% |
| Protagenic Therapeutics, Inc. | -4.49 Million USD | 6997.107% |
| Vincerx Pharma, Inc. | -42.6 Million USD | 828.212% |
| Plus Therapeutics, Inc. | -12.69 Million USD | 2544.528% |
| Acrivon Therapeutics, Inc. Common Stock | -59.85 Million USD | 618.419% |
| Rigel Pharmaceuticals, Inc. | -16.98 Million USD | 1927.242% |
| Adicet Bio, Inc. | -136.53 Million USD | 327.256% |
| Estrella Immunopharma, Inc. | -7.31 Million USD | 4344.594% |
| Quantum-Si incorporated | -91.8 Million USD | 437.985% |
| Acurx Pharmaceuticals, Inc. | - USD | -Infinity% |
| Generation Bio Co. | -133.3 Million USD | 332.771% |
| Black Diamond Therapeutics, Inc. | -86.02 Million USD | 460.699% |
| Invivyd, Inc. | -196.61 Million USD | 257.813% |
| Relay Therapeutics, Inc. | -374.15 Million USD | 182.93% |
| Quoin Pharmaceuticals, Ltd. | -9.27 Million USD | 3445.453% |
| Moolec Science SA | -52.07 Million USD | 695.834% |
| Clearside Biomedical, Inc. | -23.05 Million USD | 1445.667% |
| Longboard Pharmaceuticals, Inc. | -56.75 Million USD | 646.717% |
| Relmada Therapeutics, Inc. | 4.91 Million USD | -6219.102% |
| ALX Oncology Holdings Inc. | -158.4 Million USD | 295.881% |
| Vir Biotechnology, Inc. | -684.3 Million USD | 145.343% |
| Evaxion Biotech A/S | -21.4 Million USD | 1549.722% |
| Ocular Therapeutix, Inc. | -66.41 Million USD | 567.19% |
| Tyra Biosciences, Inc. | -79.59 Million USD | 489.843% |
| Unity Biotechnology, Inc. | -37.28 Million USD | 932.24% |
| Connect Biopharma Holdings Limited | -58.37 Million USD | 631.563% |
| Clearmind Medicine Inc. | -8.71 Million USD | 3662.117% |
| Aadi Bioscience, Inc. | -65.36 Million USD | 574.694% |
| Catalyst Pharmaceuticals, Inc. | 86.81 Million USD | -257.421% |
| CERo Therapeutics Holdings, Inc. | -2.44 Million USD | 12809.192% |
| Viking Therapeutics, Inc. | -100.82 Million USD | 407.739% |
| Keros Therapeutics, Inc. | -152.17 Million USD | 303.897% |
| Crinetics Pharmaceuticals, Inc. | -221.51 Million USD | 240.077% |
| ImmunityBio, Inc. | -436.18 Million USD | 171.136% |
| Korro Bio, Inc. | -80.9 Million USD | 483.521% |
| Kineta, Inc. | -15.71 Million USD | 2074.57% |
| BioVie Inc. | -31.95 Million USD | 1071.149% |
| Codexis, Inc. | -49.28 Million USD | 729.596% |
| Celularity Inc. | -183.94 Million USD | 268.682% |
| Virax Biolabs Group Limited | -6.6 Million USD | 4794.768% |
| Cibus, Inc. | -314.58 Million USD | 198.633% |
| Annexon, Inc. | -141.57 Million USD | 319.166% |
| Assembly Biosciences, Inc. | -64.19 Million USD | 583.339% |
| Eyenovia, Inc. | -24.1 Million USD | 1387.163% |
| Puma Biotechnology, Inc. | 44.78 Million USD | -592.846% |
| NeurAxis, Inc. | -6.66 Million USD | 4755.777% |
| Regulus Therapeutics Inc. | -30.88 Million USD | 1104.741% |
| Compass Therapeutics, Inc. | -48.47 Million USD | 740.117% |
| TFF Pharmaceuticals, Inc. | -20.74 Million USD | 1596.011% |
| Notable Labs, Ltd. | -14.4 Million USD | 2254.75% |
| IN8bio, Inc. | -28.5 Million USD | 1188.563% |
| DiaMedica Therapeutics Inc. | -19.3 Million USD | 1707.023% |
| Vera Therapeutics, Inc. | -102.01 Million USD | 404.164% |
| Lumos Pharma, Inc. | -36.57 Million USD | 948.466% |
| Liquidia Corporation | -70.05 Million USD | 542.94% |
| Mustang Bio, Inc. | -48.06 Million USD | 745.578% |
| Quantum-Si incorporated | -91.8 Million USD | 437.985% |
| Arbutus Biopharma Corporation | -70.98 Million USD | 537.106% |
| enGene Holdings Inc. Common Stock | -94.77 Million USD | 427.4% |
| ARS Pharmaceuticals, Inc. | -67.44 Million USD | 560.041% |
| 180 Life Sciences Corp. | -22.13 Million USD | 1501.842% |
| Vaxcyte, Inc. | -464.88 Million USD | 166.744% |
| Xenon Pharmaceuticals Inc. | -210.51 Million USD | 247.394% |
| Estrella Immunopharma, Inc. | -7.31 Million USD | 4344.594% |
| NKGen Biotech, Inc. Warrants | -28.54 Million USD | 1187.076% |
| Opiant Pharmaceuticals, Inc. | 5.82 Million USD | -5222.883% |
| CERo Therapeutics Holdings, Inc. | -2.44 Million USD | 12809.192% |
| Soleno Therapeutics, Inc. | -37.03 Million USD | 937.926% |
| PepGen Inc. | -83.58 Million USD | 471.233% |
| Moleculin Biotech, Inc. | -29.5 Million USD | 1151.668% |
| Solid Biosciences Inc. | -93.43 Million USD | 432.089% |
| Palisade Bio, Inc. | -12.28 Million USD | 2626.537% |
| Nutriband Inc. | -5.12 Million USD | 6158.132% |
| Conduit Pharmaceuticals Inc. | -324 Thousand USD | 95866.667% |
| Immuneering Corporation | -58.06 Million USD | 634.412% |
| Belite Bio, Inc | -31.52 Million USD | 1084.123% |
| CG Oncology, Inc. Common stock | -55.43 Million USD | 659.756% |
| GeoVax Labs, Inc. | -26.66 Million USD | 1263.473% |
| Tourmaline Bio, Inc. | -45.37 Million USD | 783.806% |
| Altimmune, Inc. | -87.93 Million USD | 452.856% |
| Peak Bio, Inc. | -1356.23 USD | 22878520.327% |
| SeaStar Medical Holding Corporation | -11.14 Million USD | 2885.064% |
| FibroBiologics, Inc. Common Stock | -15.9 Million USD | 2051.349% |
| Neurogene Inc. | -52.28 Million USD | 693.436% |
| Mirum Pharmaceuticals, Inc. | -136.49 Million USD | 327.331% |
| Kintara Therapeutics, Inc. | -8.39 Million USD | 3795.617% |
| CARGO Therapeutics, Inc. Common Stock | -93.01 Million USD | 433.574% |
| Sesen Bio, Inc. | -50.84 Million USD | 710.315% |
| argenx SE | -216.02 Million USD | 243.635% |
| NKGen Biotech, Inc. Common Stock | -28.54 Million USD | 1187.076% |
| Dianthus Therapeutics, Inc. | -48.17 Million USD | 744.09% |
| Immunome, Inc. | -28.27 Million USD | 1197.535% |
| Enveric Biosciences, Inc. | -17.13 Million USD | 1910.293% |
| Design Therapeutics, Inc. | -66.32 Million USD | 567.824% |
| Seelos Therapeutics, Inc. | -37.75 Million USD | 921.944% |
| Enliven Therapeutics, Inc. | -81.93 Million USD | 478.709% |
| Iovance Biotherapeutics, Inc. | -427.43 Million USD | 172.593% |
| Taysha Gene Therapies, Inc. | -105.19 Million USD | 394.955% |
| Inovio Pharmaceuticals, Inc. | -130.39 Million USD | 337.964% |
| Athira Pharma, Inc. | -116.7 Million USD | 365.875% |
| XOMA Corporation | -39.36 Million USD | 888.283% |
| Merus N.V. | -149.2 Million USD | 307.955% |
| Quince Therapeutics, Inc. | -31.26 Million USD | 1092.591% |
| Rezolute, Inc. | -68.42 Million USD | 553.479% |
| Clene Inc. | -43.24 Million USD | 817.569% |
| Indaptus Therapeutics, Inc. | -15.42 Million USD | 2111.932% |
| BeyondSpring Inc. | -21.54 Million USD | 1540.501% |
| Synlogic, Inc. | -55.16 Million USD | 662.506% |
| Allarity Therapeutics, Inc. | -12.08 Million USD | 2667.938% |
| Phio Pharmaceuticals Corp. | -10.64 Million USD | 3015.655% |
| Peak Bio, Inc. | -1356.23 USD | 22878520.327% |
| Werewolf Therapeutics, Inc. | -32.46 Million USD | 1055.749% |
| Krystal Biotech, Inc. | 17.9 Million USD | -1633.043% |
| Karyopharm Therapeutics Inc. | -118.42 Million USD | 362.013% |
| SpringWorks Therapeutics, Inc. | -341.34 Million USD | 190.9% |
| Lipella Pharmaceuticals Inc. | -4.6 Million USD | 6835.886% |
| MannKind Corporation | 15.12 Million USD | -1950.922% |
| Ikena Oncology, Inc. | -74.39 Million USD | 517.065% |
| Cyclerion Therapeutics, Inc. | -12.59 Million USD | 2563.94% |
| Gyre Therapeutics, Inc. | 20.32 Million USD | -1426.462% |
| Gossamer Bio, Inc. | -172.15 Million USD | 280.238% |
| CohBar, Inc. | -12.06 Million USD | 2671.608% |
| Cognition Therapeutics, Inc. | -25.5 Million USD | 1316.371% |
| NRx Pharmaceuticals, Inc. | -30.02 Million USD | 1133.419% |
| Legend Biotech Corporation | -477.87 Million USD | 164.93% |
| Mural Oncology plc | -192.72 Million USD | 261.002% |
| Disc Medicine, Inc. | -91.02 Million USD | 440.878% |
| Champions Oncology, Inc. | -5.05 Million USD | 6239.375% |
| REGENXBIO Inc. | -239.46 Million USD | 229.574% |
| Ensysce Biosciences, Inc. | -10.71 Million USD | 2994.93% |
| Anavex Life Sciences Corp. | -55.75 Million USD | 656.503% |
| Cellectar Biosciences, Inc. | -38.76 Million USD | 900.356% |
| Edgewise Therapeutics, Inc. | -112.8 Million USD | 375.06% |
| Vaxart, Inc. | -74.72 Million USD | 515.246% |
| PharmaCyte Biotech, Inc. | - USD | -Infinity% |
| Aldeyra Therapeutics, Inc. | -35.2 Million USD | 981.281% |
| Cellectis S.A. | -98.09 Million USD | 416.31% |
| Longeveron Inc. | -20.06 Million USD | 1646.78% |
| Repare Therapeutics Inc. | -114.27 Million USD | 371.529% |
| Sarepta Therapeutics, Inc. | -439.19 Million USD | 170.648% |
| Inozyme Pharma, Inc. | -74.81 Million USD | 514.752% |
| Revolution Medicines, Inc. | -430.58 Million USD | 172.062% |
| Nymox Pharmaceutical Corporation | -6.28 Million USD | 5033.757% |
| Third Harmonic Bio, Inc. | -30.78 Million USD | 1107.776% |
| ArriVent BioPharma, Inc. Common Stock | -74.59 Million USD | 515.986% |
| AN2 Therapeutics, Inc. | 4.9 Million USD | -6228.452% |
| Anixa Biosciences, Inc. | -10.96 Million USD | 2929.767% |
| Vertex Pharmaceuticals Incorporated | 4.6 Billion USD | 93.262% |
| Denali Therapeutics Inc. | -179.97 Million USD | 272.406% |
| Revelation Biosciences, Inc. | -95.2 Thousand USD | 326001.185% |
| Veru Inc. | -89.97 Million USD | 444.854% |
| Corvus Pharmaceuticals, Inc. | -26.87 Million USD | 1254.416% |
| Cingulate Inc. | -22.95 Million USD | 1451.88% |
| Passage Bio, Inc. | -98.34 Million USD | 415.518% |
| Context Therapeutics Inc. | -25.06 Million USD | 1338.136% |
| Exicure, Inc. | -15.53 Million USD | 2096.808% |
| Day One Biopharmaceuticals, Inc. | -206.06 Million USD | 250.577% |
| Oramed Pharmaceuticals Inc. | -36.97 Million USD | 939.15% |
| Scinai Immunotherapeutics Ltd. | -5.96 Million USD | 5303.841% |
| Nuvalent, Inc. | -149.49 Million USD | 307.559% |
| ABVC BioPharma, Inc. | -8.13 Million USD | 3915.398% |
| Carisma Therapeutics, Inc. | -85.89 Million USD | 461.241% |
| Unicycive Therapeutics, Inc. | -30.17 Million USD | 1128.179% |
| OmniAb, Inc. | -49.73 Million USD | 723.925% |
| Anew Medical, Inc. | -1.3 Million USD | 23952.588% |
| Fennec Pharmaceuticals Inc. | -12.36 Million USD | 2609.576% |
| Lipocine Inc. | -16.32 Million USD | 2000.939% |
| Lexeo Therapeutics, Inc. Common Stock | -66.67 Million USD | 565.403% |
| Nautilus Biotechnology, Inc. | -74.3 Million USD | 517.593% |
| SAB Biotherapeutics, Inc. | -38.13 Million USD | 913.684% |
| G1 Therapeutics, Inc. | -39.01 Million USD | 895.315% |
| Bellerophon Therapeutics, Inc. | -22.18 Million USD | 1498.747% |
| Sage Therapeutics, Inc. | -545.07 Million USD | 156.926% |
| Ocugen, Inc. | -64.82 Million USD | 578.634% |
| Mind Medicine (MindMed) Inc. | -92.57 Million USD | 435.189% |
| Q32 Bio Inc. | -86.5 Million USD | 458.702% |
| Brainstorm Cell Therapeutics Inc. | -16.92 Million USD | 1933.071% |
| Alumis Inc. Common Stock | -156.89 Million USD | 297.772% |
| Equillium, Inc. | -12.13 Million USD | 2656.303% |
| Kyverna Therapeutics, Inc. | -58.47 Million USD | 630.654% |
| Coya Therapeutics, Inc. | -7.9 Million USD | 4025.981% |
| CNS Pharmaceuticals, Inc. | -18.86 Million USD | 1745.111% |
| Dominari Holdings Inc. | -22.44 Million USD | 1482.727% |
| Edesa Biotech, Inc. | -8.19 Million USD | 3888.506% |
| vTv Therapeutics Inc. | -25.41 Million USD | 1321.014% |
| Bio-Techne Corporation | 326.66 Million USD | 5.014% |
| Agios Pharmaceuticals, Inc. | -384.86 Million USD | 180.622% |
| Harmony Biosciences Holdings, Inc. | 216.38 Million USD | -43.392% |
| Prelude Therapeutics Incorporated | -131.1 Million USD | 336.663% |
| Candel Therapeutics, Inc. | -37.43 Million USD | 928.949% |
| iTeos Therapeutics, Inc. | -151.1 Million USD | 305.349% |
| Nkarta, Inc. | -120.48 Million USD | 357.538% |
| BioCardia, Inc. | -11.56 Million USD | 2784.118% |
| Iterum Therapeutics plc | -34.58 Million USD | 997.293% |